An interventional study of C-KAD Ophthalmic Solution in Ocular Hypertension, sponsored by Chakshu Research, Inc.. Completed at 1 site in United States. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2009-06-11.
Sponsored by Chakshu Research, Inc. · Not applicable, Interventional, and Treatment
The purpose of this study is to determine the safety and tolerability of topical C-KAD Ophthalmic Solution in reducing intraocular pressure in patients with ocular hypertension.
649 studies on the registry are indexed under Ocular Hypertension; 48 are open to participants now.
This study's planned enrollment of 12 is below the median of 120 across 510 interventional studies indexed under Ocular Hypertension.
Browse Ocular Hypertension studies →Chakshu Research, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: C-KAD Ophthalmic Solution
4 drops applied daily for 150 days
Mean change in intraocular pressure from baseline
Time frame: 150 Days
This study is completed, as verified in Jun 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chakshu Research, Inc.